Expression and clinical significance of peripheral blood miRNA-146a, miRNA-155 and miRNA-186 in patients with severe pneumonia
10.3760/cma.j.cn341190-20210413-00450
- VernacularTitle:外周血miRNA-146a、miRNA-155和miRNA-186在重症肺炎患者中的表达及临床意义
- Author:
Haimin PAN
1
;
Yuan YUAN
Author Information
1. 宁波市医疗中心李惠利医院东部院区重症监护室，宁波 315000
- Keywords:
Pneumonia;
MicroRNAs;
Expression;
Prognosis;
Early diagnosis;
Treatment outcome;
Inflammatory response;
Association studies
- From:
Chinese Journal of Primary Medicine and Pharmacy
2022;29(8):1194-1198
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the expression and clinical significance of peripheral blood miRNA-146a, miRNA-155 and miRNA-186 in patients with severe pneumonia.Methods:Seventy-nine patients with severe pneumonia who received treatment in Eastern Branch of Ningbo Medical Center Li Huili Hospital from February 2019 to February 2021 were included in this study. They were divided into survival and death groups according to prognosis at 28 days after admission. An additional 60 subjects who concurrently received health examination in the same hospital were included in the control group. Peripheral blood samples were collected and serum was separated. The expression of miRNA-146a, miRNA-155 and miRNA-186 in peripheral blood was determined by real-time fluorescent quantitative PCR.Results:Acute Physiology and Chronic Health Evaluation II (APACHE II) score in the severe pneumonia group was significantly higher than that in the control group [(18.54 ± 2.83) points vs. (3.18 ± 0.57) points, t = 41.37, P < 0.05]. The relative expression of miRNA-146a in peripheral blood in the severe pneumonia group was significantly lower than that in the control group [(0.32 ± 0.07) vs. (1.08 ± 0.21), while the relative expression of miRNA-155 and miRNA-186 in the severe pneumonia group were (2.54 ± 0.46) and (3.16 ± 0.38), which were significantly higher than (0.42 ± 0.09) and (0.89 ± 0.17) in the control group ( t = 30.07, 35.16, 43.08, all P < 0.05). The relative expression of miRNA-146a in peripheral blood in the death group was significantly lower than that in the survival group [(0.25 ± 0.68) vs. (0.59 ± 0.12), t = 19.11, P < 0.001]. The relative expression of miRNA-155 and miRNA-186 in the death group were (3.97 ± 0.78) and (5.23 ± 0.86), which were significantly higher than (0.89 ± 0.21) and (1.52 ± 0.23) in the survival group ( t = 27.69, 30.29, both P < 0.05). APACHE II score was linearly negatively correlated with miRNA-146a ( r = -0.75, P = 0.015), and it was linearly positively correlated with miRNA-155 and miRNA-186 ( r = 0.82, 0.70, P = 0.002, 0.021). In the diagnosis of severe pneumonia, miRNA-146a has a sensitivity of 72.34% and a specificity of 62.50%; miRNA-155 has a sensitivity of 75.00% and a specificity of 62.96%; miRNA-186 has a sensitivity of 66.67% and a specificity of 48.65%. Conclusion:Peripheral blood miRNA-146a is lowly expressed in severe pneumonia, while miRNA-155 and miRNA-186 are highly expressed in severe pneumonia, and miRNA-146a, miRNA-155 and miRNA-186 are closely related to the prognosis of severe pneumonia.
